

Table 1: Summary of genetic polymorphisms investigated in lymphoma case-control and cohort studies.

If not otherwise indicated, odds ratios (OR) and 95% confidence intervals (in brackets) are given for the association of the rare allele carrier versus the more common allele homozygous genotype. OR with confidence intervals excluding the 1 and OR of borderline significance have been included. Subtype-specific results are indicated when available and noteworthy.

Pathway	Gene	Allele	rs number	Association with Lymphoma	Study population Cases/controls	Reference
DNA Repair						
<i>NHEJ</i>	<i>LIG4</i>	Tyr9Ile	1805388	TT vs CC: OR=0.5 (0.3-0.9) for NHL, effect seen for FL, DLCL	1172 NHL/983	(13)
	<i>RAG1</i>	Lys820Arg	2227973	AG vs AA: OR=1.3 (1.0-1.6), GG vs AA: OR=2.7 (1.4-5.0) for NHL; effect seen for FL	1172 NHL/983	(13)
<i>DSBR</i>	<i>WRN</i>	Cys1367Arg	1346044	OR=0.71 (0.56-0.91) for NHL, effect seen for DLCL, FL, MZL	518 NHL/597	(12)
		Val114Ile	4987236	OR=0.7 (0.6-1.0) for NHL	1172 NHL/983	(13)
	<i>BRCA1</i>	Glu997Gly	16941	OR=0.79 (0.62-1.02) for NHL, effect seen for DLCL	518 NHL/597	(12)
	<i>BRCA2</i>	Asn289His	766173	OR=3.97 (1.60-9.90) for T-cell NHL	518 NHL/597	(12)
		Asn372His	144848	CC vs AA: OR=1.5 (1.0-2.1) for NHL, OR=2.0 (1.2-3.3) for T-cell NHL	1172 NHL/983	(13)
	<i>XRCC3</i>	Thr241Met	861539	OR=1.62 (1.03-2.56) for FL; OR=2.60 (1.04-6.51) for MZL	518 NHL/597	(12)
		UTR C>T	3212024	OR=1.8 (1.1-2.8) for FL	430 FL/605	(14)
		UTR T>C	3212038	OR=1.5 (1.0-2.4) for FL	430 FL/605	(14)
		Intron 4 G>A	3212090	OR=1.5 (1.0-2.5) for FL	430 FL/605	(14)
	<i>NBS</i>	657del		OR=8.05 (1.71-38.0)	42 NHL, 30 HL/1289	(113)
	<i>TP53</i>	Arg72Pro	1042522	OR=1.59 (0.99-2.57) for NHL	103 NHL/440	(114)
MR						
	<i>MSH2</i>	gIVS12 -6T>C	2303428	C: 0.11% in NHL, 0.05% in Co, p<0.01 OR=1.44 (0.94-2.23) for NHL	22 NHL/50	(16)
				OR=0.45 (0.21-0.95) for FL	103 NHL/487	(17)
	<i>XRCC1</i>	Arg194Trp	1799782	OR=1.4 (1.1-1.8) for NHL, effect seen for B- and T-NHL	518 NHL/597	(12)
		Arg280His	25489	OR=2.66 (1.35-5.26) for T-NHL, OR=2.01 (1.11-3.63) for SLL/CLL	1172 NHL/983	(13)
NER	<i>ERCC5</i>	Asp1104His	17655	OR=1.46 (1.13-1.88) for NHL	518 NHL/597	(12)
	<i>ERCC2</i>	IVS5 -282G>A	1618536	GA vs GG: OR=1.5 (1.1-2.1) for FL, AA vs GG: NS	430 FL/605	(14)
		IVS16 137C>T	2070831	CT vs TT: OR=1.9 (1.1-3.2) for FL, TT vs CC: NS	430 FL/605	(14)
		Lys751Gln	13181	OR=0.64 (0.44-0.92) for DLCL, OR=0.56 (0.32-0.99) for SLL/CLL	518 NHL/597	(12)
One Carbon Metabolism	<i>MTHFR</i>	677C>T	1801133	OR=0.64 (0.39-1.05) for NHL OR=1.5 (0.97-2.2) for NHL; OR=1.8 (1.0-3.1) for FL, OR=1.8 (0.96-3.2) for DLCL	98 NHL/243	(34)
				CT vs TT: OR=0.59 (0.44-0.81) for NHL; CC vs TT: OR=0.81 (0.55-1.20) for NHL	337 NHL/731	(22)
		1298A>C	1801131	AC vs AA: OR=1.26 (0.96-1.65) for NHL, CC vs AA: OR=1.27 (0.70-2.31) for NHL	372 NHL, HL/500	(24)
	<i>MTR</i>	Asp919Gly	1805087	GG: OR=3.59 (1.11-11.5) for NHL OR=0.41 (0.19-0.88) for FL, NS for DLCL	98 NHL/243	(34)
				OR=1.3 (0.99-1.7) for NHL, OR=1.3 (0.88-2.0) for DLCL, OR=1.2 (0.78-1.7) for FL	151 NHL, 90 MM/299	(28)
				OR=0.26 (0.09-0.74) for PCNSL	337 NHL/771	(22)
				GG: OR=2.00 (1.05-3.80) for NHL	31 PCNSL/142	(29)
				OR=0.49 (0.29-0.82) for FL	372 NHL, HL/500	(24)
	<i>MTRR</i>	66A>G	1801394	A-allele: OR=0.69 (0.50-0.96) for NHL	172 FL/206	(30)
	<i>TYMS</i>	<i>TYMS</i> 28-bp 2R> 3R		2R (+) vs 2R (-): OR=1.63 (1.05-2.53) for NHL	120 ALL*, 200 NHL/257	(25)
				2R3R: OR=1.48 (1.12-1.97) for NHL; OR=1.45 (0.96-2.2) for FL;	108 NHL/494	(33)
				OR=3.38 (1.30-8.82) for MZL, NS for DLCL	589 NHL/755	(23)
				2R (-) vs 2R (+): OR=2.12 (1.32-3.4) for FL	172 FL/206	(30)
		1494del6 <i>TYMS</i> IVS6 -68C>T	16430, 1059394, 699517, 2790	6bp(-)(-), IVS6 -68TT, 1053TT genotypes (all in complete LD): OR=0.57 (0.34-0.94) for NHL, OR=0.29 (0.10-0.82) for DLCL, OR=0.67 (0.32-1.4) for FL	337 NHL/731	(22)
		<i>TYMS</i> 1053C>T <i>TYMS</i>				

		1122A>G				
Immune regulation <i>Cytokines</i>		1494del6	16430	Homozygous 6-bp deletion: OR=1.61 (0.99-2.60) for DLCL, NS for NHL and FL	589 NHL/755	(23)
	<i>SHMT1</i>	1420C>T	1979277	OR=0.46 (0.23-0.93) for NHL TT vs. CC: OR=0.75 (0.51-1.09) for NHL	108 NHL/494	(33)
	<i>RFC</i>	80G>A	1051266	NS for NHL and DLCL, 80AA: OR=1.44 (0.94-2.22) for FL	589 NHL/755	(23)
	<i>CBS</i>	844ins68 (splice) variant		OR=2.43 (0.90-6.61) for PCNSL	31 PCNSL/142	(29)
	<i>TNF</i>	-308G>A	1800629	A-allele in NHL Ca: OR=6.7, p<=0.0001 OR=3.18 (1.57-8.3) for CLL OR=1.19 (1.05-1.33) for NHL, GA vs GG: OR=1.29 (1.10-1.51) for DLCL, AA vs GG: OR=1.65 (1.16-2.34)] for DLCL, NS for FL	44 NHL/106 73 CLL 3586 NHL/ 4018	(115) (116) (37)
				AA vs GG: OR=3.63 (p=0.028) for NHL	194 NHL/160	(117)
		-857C>T	2507961	OR=2.34 (1.2-4.7) for NHL OR=0.33 (0.15-0.75) for NHL OR=1.8 (1.1-2.8) for MALT compared to H. pylori positive (HP +) controls OR=1.9 (1.0-3.6) for MALT compared to blood donors OR=0.59 (0.42-0.84) for NHL, OR=0.40 (0.23-0.68) for FL	71 ATL, 80 healthy HTLVI 70 maltoma/ 210 144 GMALT/594 HP+ 545 NHL/498	(53) (52) (51) (50)
		-863C>A	1800630	OR=1.53 (1.03-2.27) for DLCL	545 NHL/498	(50)
	<i>LTA</i>	252 A>G	909253	OR=0.59 (0.37-1.04) for FL 252GG: OR=1.18 (0.96-1.44) for NHL, OR=1.47 (1.18-1.84) for DLCL, but not FL.	121 FL/88 3586 NHL/ 4018	(118) (37)
	<i>IL1B</i>	-31C>T	1143627	OR=0.73 (0.48-1.11) for NHL, 0.61 (0.36-1.04) for DLCL	241 NHL/372	(119)
	<i>IL1RN</i>	Intron 2, 86 bp VNTR		*2/*2 genotype: OR=5.51 (2.16-14.07) for GMZL	66 GMZL/163	(92)
	<i>IL4</i>	-1098T>G	2243248	OR=1.49 (1.05-2.11) for NHL, OR=3.84 (1.79-8.22) for T-NHL OR=1.59 (1.00-2.54) for DLCL	518 NHL/597 545 NHL/498	(48) (50)
	<i>IL4R</i>	-29429C>T	2107356	OR =1.19 (0.91-1.55 for NHL, OR=2.6 (1.04-6.21) for T-NHL TT vs CC: OR=1.66 (1.13-2.42) for DLCL	518 NHL/597 1,172 NHL/982	(48) (49)
	<i>IL5</i>	-745C>T	2069812	TT vs CC: OR=1.63 (1.04-2.54) for NHL, OR=2.28 (1.25-4.15) for DLCL	518 NHL/597	(48)
	<i>IL6</i>	-174 G>C	1800795	CC vs GG: OR=0.29 (0.1-0.87) for HL NS for cHL, CC vs GG OR=0.13 (0.02-1.06) for NLPHL OR=1.6 (0.85-3.01) for CTCL NS for NHL, OR=0.46 (0.23-0.92) for T-NHL	88 young adult HL/their twin, 87 408 HL/349 63 CTCL/105 518 NHL/597	(54) (55) (120) (48)
		-596A>G,-597G>A,-	1800797	OR=2.68 (1.39-5.16) for CTCL NS for NHL, OR=0.38 (0.19-0.78) for T-NHL	63 CTCL/105 518 NHL/597	(120) (48)
	<i>IL7R</i>	Ex4+33G>A	1494555	GG vs AA: OR=0.61 (0.38-0.99) for B-NHL; OR=2.32 (1.03-5.25) for T-NHL	518 NHL/597	(48)
	<i>IL10</i>	-819C>T	1800871	NS for NHL, DLCL, OR=1.48 (0.98-2.25) for FL	518 NHL/597	(48)
		-592C>A	1800872	CC vs AA: OR=1.6 (1.1-2.3) for AIDS related NHL NS for NHL, DLCL, OR=1.47 (0.97-2.23) for FL	138 of AIDS ly./1019 HIV+ 518 NHL/597	(121) (48)
		-1082A>G	1800896	OR=1.97 (1.07-3.66) for aggressive lymphoma, HL: NS G-allele frequency in DLCL (72%) vs. Controls (60%) p=0.023 OR=1.09 (0.97-1.22) for NHL, OR=1.17 (1.00-1.37) for DLCL	156 NHL + HL 199 DLCL/112 3586 NHL/ 4018	(122) (123) (37)
	-3575T>A	1800890	GG vs AA: OR=1.53 (1.08-2.17) for NHL, OR=1.68 (1.15-2.44) for B-NHL OR=1.11 (1.01-1.23) for NHL, OR=1.22 (1.06-1.40) for DLCL AA vs TT: OR=1.94 (1.31-2.87) for NHL, OR= 2.05 (1.36-3.11) for B-NHL AA vs TT: OR=1.84 (1.10-3.08) for DLCL	518 NHL/597 3586 NHL/ 4018 518 NHL/597 545 NHL/498	(48) (37) (48) (50)	
	Ex5+210T>C	3024496	CC vs TT: OR=1.55 (1.07-2.24) for NHL and OR=1.67 (1.13-2.47) for B-NHL	518 NHL/597	(48)	
	IVS1-286G>T	3024491	TT vs GG: OR=1.54 (1.07-2.23) for NHL	518 NHL/597	(48)	

	<i>IL10RA</i>	Ser159Gly A>G	3135932	OR=0.81 (0.65-1.02) for all lymphoma, OR=0.51 (0.31-0.84) for HL	678 NHL, HL, MM/669	(124)
	<i>IL12B</i>		3212227	OR=1.48 (1.03-2.12) for SLL	1,172 NHL/982	(49)
	<i>IL13</i>	Gln144Arg	20541	OR=1.53 (1.07-2.20) for SLL	1,172 NHL/982	(49)
		1069C>T	1800925	OR=1.50 (1.04-2.14) for SLL	1,172 NHL/982	(49)
Chemokines	<i>IFNGR1</i>	IVS6-4G>A	3799488	NS for NHL, OR=0.52 (0.29-0.96) for FL	518 NHL/597	(48)
	<i>IFNGR2</i>	Ex7 -128C>T	1059293	OR=0.78 (0.59-1.03) for NHL, OR=0.67 (0.46-0.98) for DLCL	545 NHL/498	(50)
	<i>CCR5</i>	delta32	333	OR=0.32 (0.13-0.79) for AIDS-related NHL RR=0.20 (0-0.9) for AIDS related NHL	95 HIV-infected NHL/95 HIV+ 746 HIV-infected persons	(125) (126)
	<i>CXCL12</i>	801G>A		3'A/+ : OR=2.5 (1.3-4.8) for AIDS related NHL, 3'A/3'A : OR=5.1 (1.6-14)	746 HIV-infected persons	(126)
	<i>IL8RB</i>	Ex3-1010A>G	1126580	OR=0.77 (0.62-0.96) for NHL, GG vs AA: OR=0.45 (0.26-0.79) for DLCL	1,172 NHL/982	(49)
	Innate Immunity	<i>TLR2</i>	-16933T>A	4696480	OR=2.82 (1.43-5.59) for FL, OR=0.61(0.38-0.95) for CLL	678 NHL, HL, MM/669
<i>TLR4</i>		Asp299Gly	4986790	OR= 0.37 (0.13-1.03) for NHL OR=0.92 (0.71-1.2) for NHL, OR=0.67 (0.45-0.99) for DLCL OR=2.76 (1.12-6.81) for MALT, OR=1.80 (0.99-2.26) for HL	87 gastric MALT/594 HP+ 904 NHL/1442	(67) (64)
<i>TLR9</i>		-1486T>C	187084	OR=1.61 (0.96-2.71) for FL	678 NHL, HL, MM/669	(124)
<i>CARD 15</i>		1007fs	2066847	CC vs --: OR=3.1 (1.1-8.8) for NHL	904 NHL/1442	(64)
		Arg702Trp	2066844	OR=2.4 (1.0-5.6) for MALT lymphoma	83 gastric MALT/308 HP+	(65)
<i>FCGR2A</i>		His165Arg	1801274	OR=1.31 (1.07-1.61) for NHL, effect seen for B- and T-cell lymphoma OR=1.50 (0.98-2.29) for DLCL	1,172 NHL/982 545 NHL/498	(49) (50)
Oxidative Stress	<i>NOS2A</i>	Ser608Leu	2297518	Leu/Leu: OR=2.2 (1.1-4.4) for NHL, OR=3.4 (1.5-7.8) for DLCL and OR=2.6 (1.0-6.8) for FL	1,172 NHL/982	(72)
	<i>MPO</i>	-463 G>A	2333227	OR=1.3 (1.1-1.5) for NHL, OR=1.3 (1.0-1.7) for DLCL, OR=1.5 (1.0-2.4) for MZL	1,172 NHL/982	(72)
	<i>SOD2</i>	Val16Ala	4880	Ala/Ala: OR=1.3 (1.0-1.6) for B-cell Ly, OR=1.3 (1.0-1.89 for DLCL, NS for FL NS for NHL, OR=0.45 (0.60-1.12) for MZL	1,172 NHL/982 928 NHL/1446	(72) (75)
	<i>GPX1</i>	Pro200Leu(Pro197Leu)	1050450	OR=1.31 (1.06-1.62) for NHL, effect seen in DLCL and FL	928 NHL/1446	(75)
	<i>PPARG</i>	His477His	3856806	OR=1.4 (1.0-2.1) for FL, OR=0.5 (0.3-0.9) for SLL, NS for DLCL	1,172 NHL/982	(72)
	<i>GPX1</i>	Pro200Leu(Pro197Leu)	1050450	OR=1.31 (1.06-1.62) for NHL, effect seen in DLCL and FL	928 NHL/1446	(75)
Energy Regulation	<i>LEP</i>	-2548G>A	7799039	GA vs GG: OR=1.3 (1.0-1.7) for NHL; AA: OR=1.4 (1.0-1.9) for NHL	699 NHL/914	(82)
		19A>G	2167270	OR = 1.6 (1.1-2.3) for NHL, OR=1.9 (1.0-3.6) for FL 19AA vs GG: OR=0.5 (0.3-0.8) for FL, NS for NHL and DLCL	376 NHL/805 699 NHL/914	(81) (82)
	<i>LEPR</i>	Gln223Arg	1137101	NS for NHL, 223RR vs QQ: OR=1.9 (1.0-3.6) for FL among women	699 NHL/914	(82)
	<i>NPY</i>	-485T>C	16147	OR=1.5 (1.1-2.2) for NHL, OR=2.0 (1.2-3.6) for FL, NS for DLCL	308 NHL/684	(83)
		1258G>A	11557492	OR=1.6 (1.1-2.2) for NHL, OR=2.0 (1.1-3.5) for FL, NS for DLCL	308 NHL/684	(83)
		5671C>T	5574	OR=1.6 (1.1-2.2) for NHL, OR=1.8 (1.1-3.0) for FL, NS for DLCL	308 NHL/684	(83)
Hormone Production		1128 T>C	16139	OR=2.3 (1.1-4.9) for FL, NS for DLCL	308 NHL/684	(83)
	<i>GHRL</i>	-4427G>A	1629816	OR=0.78 (0.59-1.0) for NHL, OR=0.61 (0.40-0.94) for DLCL	308 NHL/684	(83)
	<i>CYP17A1</i>	-34T>C	743572	CC vs TT: OR=1.4 (0.95-2.1) for NHL, OR=2.0 (1.1-3.5) for DLCL	308 NHL/684	(87)
		137G>A	6162	CC vs TT: OR=1.4 (1.02-2.03) for NHL, OR=1.76 (1.14-2.71) for DLCL	620 NHL/762	(88)
		195C>A	6163	AA vs GG: OR=1.4 (0.95-2.1) for NHL, OR=1.8 (1.0-3.3) for DLCL	308 NHL/684	(87)
		-270A>C	3781287	AA vs CC: OR=1.5 (0.99-2.2) for NHL, OR=2.1 (1.2-3.6) for DLCL	308 NHL/684	(87)
		IVS2 105A>C	743575	CC vs AA: OR=1.5 (0.99-2.2) for NHL, OR=1.7 (0.92-3.0) for DLCL CC vs AA: OR=1.5 (0.93-2.5) for NHL, OR=2.1 (1.1-4.2) for DLCL	308 NHL/684 308 NHL/684	(87) (87)
		75C>T	3740397	CC vs AA: OR=1.37 (0.91-2.05) for NHL, OR=1.61 (0.95-2.75) for FL	620 NHL/762	(88)
		2930G>T	4919685	GG vs CC: OR=1.6 (1.1-2.5) for NHL, OR=2.3 (1.3-4.1) for DLCL	308 NHL/684	(87)
				TT vs GG: OR=2.2 (1.1-4.3) for DLCL	308 NHL/684	(87)

Xenobiotic	<i>COMT</i>	108/158Val>Met 701A>G	4680 737865	NS for NHL, Met/Met: OR=2.0 (0.84-4.9) for FL in women NS for NHL, OR=0.42 (0.23-0.78) for FL in women	308 NHL/684 308 NHL/684	(87) (87)	
	<i>PRL</i>	-1149G>T -1488A>G	1341239 849877	TT vs GG: OR=0.64 (0.41-1.0) for NHL, OR=0.53 (0.26-1.0) for FL GG vs AA: OR=0.70 (0.45-1.1) for NHL, OR=0.55 (0.27-1.1) for FL	308 NHL/684 308 NHL/684	(87) (87)	
	<i>GSTT1</i>	Null		OR=3.22 (1.94-3.22) for NHL OR=1.9 (1.04-3.46) for HL OR=9.51 (4.57-19.81) for GMZL OR=1.8 (1.1-3.0) for MALT	169 NHL/205 90 HL/176 66 GMZL/163 75 MALT/321	(91) (93) (92) (94)	
	<i>GSTP1</i>	Ile105Val (1548A>G)	947894	NS for NHL, Val/Val: OR=2.08 (1.05-4.14) for HL Val/Val: OR=1.8 (0.6-5.1) for MZL, OR=0.2 (0.1-0.96) for DLCL	219 HL and NHL/455 389 NHL/535	(95) (96)	
	<i>PON1</i>	Gln192Arg Leu55Met	662 854560	Arg/Arg: OR=2.55 (1.37-4.55) for NHL Met/Met vs Leu/Leu : OR=1.36 (0.96-1.95) for NHL, effect seen for FL and T-NHL	169 NHL/205 1,172 NHL/982	(91) (127)	
	<i>CYP1B1</i>	Val432Leu	1056836	OR=1.27 (0.97-1.65) for NHL, effect seen across B-cell subtypes, but not T-cell lymphoma	1,172 NHL/982	(127)	
	<i>CYP2E1</i>	Intron 6 DraI -1054C>T (Rsal)	2031920	CD: OR=0.62 (0.37-1.05) for NHL; CC: OR=0.68 (0.41-1.13) for NHL OR=0.59 (0.37-0.93) for NHL, effect seen in all histologic subtypes	219 HL, NHL/455 1,172 NHL/982	(95) (127)	
	<i>EPHX1</i>	Tyr113His -1054C>T (Rsal)	1051740 2031920	Tyr/His: OR=0.45 (0.26-0.76) for lymphoma among males, His/His: NS OR=0.59 (0.37-0.93) for NHL, effect seen in all histologic subtypes	219 HL, NHL/455 1,172 NHL/982	(95) (127)	
	<i>NAT1</i>	*3, *4, *10, *11		Slow acetylator genotype: OR=1.4 (0.9-2.3) for NHL in women, NS for men	389 NHL/535	(96)	
	<i>NAT2</i>	*3, *4, *10, *11, *14 *4, *5, *6, *7		*10*10 vs other genotypes: OR=1.60 (1.04-2.46) for NHL, OR=2.06 (1.12-3.79) for FL Intermediate/rapid vs slow: OR=1.21 (1.00-1.47) for NHL, OR=1.50 (1.11-2.02) for FL	1136 NHL/922 1136 NHL/922	(101) (101)	
	Cell Cycle Regulation	<i>CCND1</i>	Pro241Pro	603965	AG vs GG: OR=1.1 (0.9-1.3) and AA vs GG: OR=1.4 (1.1-1.8) for NHL	1,172 NHL/982	(128)
	Other	<i>BCL6</i>	397G>C -195C>T		OR=1.52 (1.13-2.05) for FL CC vs TT: OR=2.2 (1.5-3.3) for NHL, effect seen in B-and T-NHL, CLL, DLCL, FL	85 FL/188 (129) (130)	
		<i>CASP3</i>	Ex8-280C>A Ex8+567T>C	6948 1049216	OR=0.7 (0.5-1.0) for B cell lymphoma, OR=0.5 (0.3-0.8) for FL OR=0.8 (0.6-1.0) for NHL, OR=0.4 (0.3-0.7) for FL	461 NHL/535 461 NHL/535	(131) (131)
		<i>CASP9</i>	Ex5+32G>A	1052576	AA vs GG: OR=0.7 (0.5-1.0) for NHL, AA/AG vs GG: OR=0.6 (0.4-1.0) for FL	461 NHL/535	(131)
		<i>CTLA4</i>	-49A>G	231775	OR=2.0 (1.2-3.2) for NHL GG vs AA: OR=4.1 (0.9-18.2) for MALT lymphoma	100 NHL/128 62 MALT/250	(132) (133)
			-318C>T	5742909	CT vs CC: OR=0.3 (0.1-0.9) for MALT lymphoma (AT) ₈₂ vs others: OR=1.6 (1.1-2.4) for NHL	62 MALT/250 100 NHL/128	(133) (132)
	<i>HSPA1B</i>	Pst at 1267	1061581	P2P2: OR=18.2, p<=0.0001	44 NHL/106	(115)	
	<i>HSPA1L</i>	Nco at 2437	2227956	OR=4.9 (p<=0.0002)	44 NHL/106	(115)	
	<i>JAK3</i>	Ex24 291T>C	3008	OR=4.1 (1.23-13.67) for T-NHL	518 NHL/597	(48)	
	<i>NPAS2</i>	Ala394Thr	2305160	OR=0.66 (0.51-0.85) for NHL, effect seen for DLCL and FL	455 NHL/527	(134)	
	<i>P73</i>	Ex2 4G>A, 14C>T	2273953, 1801173	OR=1.46 (0.93-2.30) for NHL	103 NHL/440	(114)	
	<i>TGFB1</i>	Leu10Pro	1982073	OR=0.71 (0.55-0.91) for NHL, OR=0.66 (0.47-0.93) for FL	545 NHL/498	(50)	

Abbreviations: AIDS-Ly (AIDS-associated lymphoma), ATL (adult T-cell leukemia/lymphoma), BER (base excision repair); CTCL (cutaneous T-cell lymphoma), DLCL (diffuse large B-cell lymphoma), DSB (double-strand break repair); GMALT (gastric mucosa-associated lymphoid tissue lymphoma), HP+ (Helicobacter pylori positive), MZL (marginal zone lymphoma), MR (mismatch repair); NHEJ (non-homologous end-joining); NS (not statistically significant), NER (nucleotide excision repair); PCNSL (primary central nervous system lymphoma), vs (versus).